by Ellen Foster Licking
The New Ophthalmic Drug Players
Unmet medical need and market size continue to drive venture investors to ophthalmic drug plays focused on diseases that blind. This interest is fueled by a stable pool of acquirers and the ability to in-license innovative, clinically validated compounds, providing VCs with a jump start to a potential exit.
More from Archive
More from Scrip
• By
Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
• By
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.